financetom
Business
financetom
/
Business
/
Airbnb Insider Sold Shares Worth $1,496,801, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Airbnb Insider Sold Shares Worth $1,496,801, According to a Recent SEC Filing
Mar 8, 2024 2:18 PM

04:53 PM EST, 03/08/2024 (MT Newswires) -- Nathan Blecharczyk, 10% Owner, Director, Chief Strategy Officer, on March 06, 2024, sold 9,186 shares in Airbnb ( ABNB ) for $1,496,801. Following the Form 4 filing with the SEC, Blecharczyk has control over a total of 190,036 shares of the company, with 183,425 shares held directly and 6,611 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1559720/000095017024028705/xslF345X03/ownership.xml

Price: 164.75, Change: -0.16, Percent Change: -0.1

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Judge Rules Against New York Law Requiring Uber, DoorDash to Share Data With Restaurants
Judge Rules Against New York Law Requiring Uber, DoorDash to Share Data With Restaurants
Oct 3, 2024
06:59 AM EDT, 09/25/2024 (MT Newswires) -- A federal judge ruled on Tuesday that a New York City law requiring food delivery services such as Uber (UBER) Eats, DoorDash ( DASH ) and Grubhub to share customer names and contact details with restaurants is unconstitutional, media outlets reported. The judge ruled that the 2021 law meant to help restaurants recover...
2seventy bio, Bristol Myers Discontinue Phase 3 Abecma Study; Shares Fall Pre-Bell
2seventy bio, Bristol Myers Discontinue Phase 3 Abecma Study; Shares Fall Pre-Bell
Oct 3, 2024
06:57 AM EDT, 09/25/2024 (MT Newswires) -- 2seventy bio (TSVT) said Wednesday it would discontinue enrollment for the ongoing phase 3 study of Abecma with lenalidomide maintenance as treatment for newly diagnosed multiple myeloma due to scarce eligible patients for the trial. Shares of the company were down 7.3% in recent premarket activity. Treatments for NDMM have improved considerably since...
--Merck Says Phase 3 Trial of Colorectal Cancer Combination Therapy Did Not Meet Primary Endpoint
--Merck Says Phase 3 Trial of Colorectal Cancer Combination Therapy Did Not Meet Primary Endpoint
Oct 3, 2024
06:58 AM EDT, 09/25/2024 (MT Newswires) -- Price: 114.69, Change: -0.27, Percent Change: -0.23 ...
Merck's colorectal cancer therapy fails late-stage trial
Merck's colorectal cancer therapy fails late-stage trial
Oct 3, 2024
(Reuters) -Merck ( MRK ) said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of colorectal cancer. The company said patients who took its experimental drug favezelimab in combination with Keytruda did not show significant improvement in overall survival compared to standard-of-care treatment. The combination therapy is...
Copyright 2023-2026 - www.financetom.com All Rights Reserved